SecBot SecBot

ABBV

AbbVie Inc.
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0001551152 Biotech & Drug Discovery
$294.64 −0.39 (−0.13%)
Nov 16 4:00 PM ET · prev $295.03
Market cap
$520.5B
Mega cap
Consensus
Buy
82% Buy or better · 38 analysts
Median target
$317.00
+8% · range $237.00–350.00
1 year
+25.9%
from $234.00 · Nov 17
30 days
+3.2%
from $285.42
52-week range
$197.38–295.03
−0% from high · low Apr 27
Avg volume 20D
5.05M
shares / day
Short interest
15.81M
≈0.9% of shares · +1.5%
Days to cover
3.3
at average volume
Insider net
−$30.8M
0 buyers · 4 sellers · since Feb 18
New fund stakes
5
Q2 2026 13F · 4 exits
Reddit crowd
50°
Neutral · 8 mentions this week
SecBot read BULLISH 10 reports · 90 days
Balance 0 bearish · 3 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 8/10

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $30.8M.

  • InstitutionsBULLISH

    Q2 2026: 57 added (5 new), 34 trimmed or exited. Largest new: Gqg Partners $483.6M, Point72 Asset Management, $92.3M.

  • AnalystsBULLISH

    31 of 38 rate it Buy or better. Median target $317.00 (+8%).

  • Short sellersSTEADY

    Short interest +1.5% to 15.81M shares. 3.3 days to cover, ≈0.9% of shares.

  • TrendUPTREND

    7% above its 50-day average. New closing high $295.03 on Nov 13.

  • SocialQUIET

    Crowd 50° (neutral) this week from 8 mentions: 0 bullish, 0 bearish. No setup is alerting. Excludes 1 subscriber-only day.

Who's buying

13F· Q2 2026
5
new positions
4
exits
$575.9M
in new stakes · top 2 shown
FundMoveSharesValue
WELLINGTON MANAGEMENT GROUP LLPTRIM5,055,589$1.3B
Boston PartnersADD4,784,316$1.2B
CITADEL ADVISORS LLCDOUBLED3,169,783$797.6M
MARSHALL WACE, LLPDOUBLED2,990,512$752.5M
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am MainDOUBLED2,885,557$726.1M
TD ASSET MANAGEMENT INCTRIM2,578,333$648.8M
VOYA INVESTMENT MANAGEMENT LLCADD2,374,888$597.6M
D. E. Shaw & Co., Inc.DOUBLED2,102,316$529.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

38 analysts
Buy 82% rate it Buy or better
Strong Buy10Buy21Hold7Sell0Strong Sell0
12-month targets · 26 analysts

Price is inside the target range. Median implies +8%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Nov 2, 2026UBS
MAINTAIN
MAINTAINNeutral
Nov 2, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Nov 2, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Nov 2, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Nov 2, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 15, 2026 Clinical trial readout
🔒 Fresh data, subscribers only
Nov 12, 2026 Insider
Stewart Jeffrey Ryan gifted 3,450 shares
EVP, CHIEF COMMERCIAL OFFICER
Nov 9, 2026 SEC
Jeffrey R. Stewart, an officer of AbbVie, filed a Form 144 notice of intent to sell 40,619 shares of common stock…
144 · Impact 2/10
Nov 9, 2026 Insider
Stewart Jeffrey Ryan acquired via exercise 24,549 shares
EVP, CHIEF COMMERCIAL OFFICER @ $93.50 ($2.3M)
Nov 9, 2026 Insider
Stewart Jeffrey Ryan sold 40,619 shares
EVP, CHIEF COMMERCIAL OFFICER @ $293.60 ($11.9M)
Nov 2, 2026 SEC
AbbVie disclosed that Class II director Jennifer L. Davis resigned from the board effective November 2, 2026…
8-K · Impact 2/10
Oct 29, 2026 SEC
The D.C. District Court granted AbbVie partial summary judgment, ruling that CMS misinterpreted the IRA's…
COURT-RULING · Impact 7/10
Oct 29, 2026 Event
ABBVIE INC. v. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES et al
Court ruling (dcd). Docket: 1:26-cv-00431

Insider ledger

Form 4
$0
bought · 0 insiders
$30.8M
sold · 4 insiders
DateInsiderTypeValue
Nov 12, 2026
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
Nov 12, 2026
GIFT3,450 sh
Nov 9, 2026
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
Nov 9, 2026
EXERCISE$2.3M
Nov 9, 2026
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
Nov 9, 2026
SELL$11.9M
Nov 9, 2026
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
Nov 9, 2026
EXERCISE$1.8M
Sep 30, 2026
Quaggin Susan E
Director
Sep 30, 2026
AWARD$15.4K
Sep 30, 2026
RAPP EDWARD J
Director
Sep 30, 2026
AWARD$33.7K
Aug 14, 2026
Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
Aug 14, 2026
EXERCISE$2.6M
Aug 14, 2026
Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
Aug 14, 2026
SELL$8.2M

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Congressional trades
ABBV trades disclosed by members of Congress, with disclosure delay.
3 members · 3 buys / 3 sells
DateMemberType AmountDisclosed
Oct 7, 2026 Ro KhannaDHouse Spouse account · AbbVie Inc BUY $15K–$50K Nov 5, 2026 +29d
Sep 14, 2026 Pete SessionsRHouse AbbVie Inc SELL $15K–$50K Sep 18, 2026 +4d
Sep 4, 2026 Ro KhannaDHouse Spouse account · AbbVie Inc SELL $15K–$50K Oct 7, 2026 +33d
May 15, 2026 Ro KhannaDHouse Spouse account · AbbVie Inc BUY $15K–$50K Jun 9, 2026 +25d
May 5, 2026 Josh GottheimerDHouse Joint account · AbbVie Inc SELL $1K–$15K Jun 3, 2026 +29d
May 1, 2026 Ro KhannaDHouse Child account · AbbVie Inc BUY $15K–$50K Jun 9, 2026 +39d

Washington

Corporate Lobbying

91 lobbying filings and 11 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
15,813,441
shares short
+1.5%
vs prior settlement
3.3
days to cover
≈0.9%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
20 drugs tracked · Drug pipeline →
Recent
Nov 15, 2026
Trial readout
🔒 Fresh data, subscribers only
Nov 15, 2026
Trial readout
🔒 Fresh data, subscribers only
Nov 15, 2026
Trial readout
🔒 Fresh data, subscribers only
Nov 16, 2026
Clinical Trial
🔒 Fresh data, subscribers only
Nov 13, 2026
Clinical Trial
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
Phase 3 · COMPLETED
Reddit Mentions per day, 14 days
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 8 1 in posts · 7 in comments
Recent posts
Recent comments
All social signals and their track records

SecBot reports

22 filings · 8 bullish · 1 bearish · 1 mixed · 12 neutral
All ABBV filing & press-release reports (22)